::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

TREATMENT OF HEPATITIS C VIRUS IN HIV/HCV CO-INFECTION

AUTHORS:

Dr. Ali Haider Tariq, Dr. Tayyaba Shahbaz, Dr Sana Abdul Jabbar

ABSTRACT:

Introduction: Hepatitis C is an RNA flavivirus that infects 4 million people in the United States making up approximately 1.8% of the population, and 150-200 million worldwide. In persons with HIV, its prevalence is estimated to be approximately 50%. Objectives: The basic aim of the study is to find the treatment of Hepatitis C Virus in HIV/HCV co-infection in Pakistan. Material and methods: This cross sectional study was conducted at Jinnah hospital, Lahore during June 2019 to December 2019. This study was done to find the treatment of hepatitis C virus in HCF co-infection in Pakistan. The treatment of hepatitis C virus (HCV) infection is rapidly evolving. Patients with HCV/HIV coinfection treated with all-oral, direct-acting antiviral (DAA) HCV regimens can achieve sustained virologic response (HCV cure) at rates comparable to those of patients with HCV mono-infection. Results: Initiation of ART for persons with HCV/HIV coinfection should follow the recommendations for all persons with HIV infection, taking into account the need for concurrent HCV treatment with oral DAA regimens, drug-drug interaction potentials, and the individual’s HBV status. The same regimens that are recommended for initial treatment of HIV in most ART-naive persons are also recommended for persons with HCV/HIV coinfection. Conclusion: It is concluded that In order to maximize therapeutic efficacy, we will need to determine the immunological defect that is responsible for the diminished cellular immune response to HCV in HIV/HCV co-infected patients.